Infant Bacterial Therapeutics
80 SEK +3,9%Vær den første som følger denne virksomhed
Infant Bacterial Therapeutics, also known by the name IBT, is a pharmaceutical company. The company develops drugs to treat and prevent children from developing common ailments and diseases that occur at premature birth. Common is that disorders can occur in the development of microorganisms such as microbiome. The largest operations are in the Nordic market. The company's head office is located in Stockholm.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
IBT B
Daglig lav / høj pris
76,2 / 80
SEK
Markedsværdi
1,08 mia. SEK
Aktieomsætning
121,33 t SEK
Volumen
1,6 t
Finanskalender
Delårsrapport
07.05.2024
Generalforsamling
08.05.2024
Delårsrapport
28.08.2024
Delårsrapport
14.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
SIX SIS AG, W8IMY | 11,0 % | 8,4 % |
Fjärde AP-fonden | 10,0 % | 7,7 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Infant Bacterial Therapeutics AB (publ), Interim report January 1-December 31, 2023
Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2023
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools